Recent studies on retatrutide, a dual stimulant for incretin hormone and gastric inhibitory polypeptide, demonstrate significant findings in treating weight gain and type 2 glucose intolerance. Early evidence from clinical assessments reveal considerable reductions in body mass and improved glucose control. Additional research is directed website o